|
|
MVA virus vaccine vector |
|
Vaxvec ID |
78 |
|
Vaccine Vector Name |
MVA virus vaccine vector |
|
Alternative Names |
Modified Vaccinia Ankara virus vaccine vector |
|
Vector VO ID |
VO_0001107
|
|
Preparation |
MVA was derived from chorioallantois vaccinia Ankara (CVA), a Turkish smallpox vaccine strain, by serial passaging (> 570 passages) in primary chicken embryo fibroblast (CEF) cells (Mayr and Munz, 1964). |
|
Safety |
During passaging, the host range of the virus was severely restricted. Host range restriction of this virus in cell culture is partially governed by the six major deletions and is to a large extent based on additional mutations among the multitude of genes with altered amino acid sequence compared to the parental CVA virus. As a result, MVA is unable to productively infect many mammalian cells. As a third-generation smallpox vaccine, MVA has an excellent safety profile and immunogenicity in the clinic. In addition, MVA is well tolerated and immunogenic when administered to immunocompromised patients infected with HIV (Wennier et al., 2013). |
|
Description |
Modified vaccinia virus Ankara (MVA) has been shown to be suitable for the generation of experimental vaccines against cancer and infectious diseases (Wennier et al., 2013). |
| Related Vaccine(s) |
|
| References |
Mayr and Munz, 1964: Mayr A, Munz E. [Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures]. Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. 1. Abt. Medizinisch-hygienische Bakteriologie, Virusforschung und Parasitologie. Originale. 1964; 195(1); 24-35. [PubMed: 5890664].
Wennier et al., 2013: Wennier ST, Brinkmann K, Steinhäußer C, Mayländer N, Mnich C, Wielert U, Dirmeier U, Hausmann J, Chaplin P, Steigerwald R. A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses. PloS one. 2013; 8(8); e73511. [PubMed: 23951355].
|
|
